UNSPSC 51413211: Vardenafil hydrochloride

This classification denotes a cgmp phosphodiesterase inhibitor with the molecular formula C23H32N6O4S.ClH.3H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5M8S2CU0TS, chemically known as 2-(2-ethoxy-5-(4-ethylpiperazin-1-yl-1-sulfonyl)phenyl)-5-methyl-7-propyl-3h-imidazo(5,1-f)(1,2,4)triazin-4-one dihydrochloride but more generally known as vardenafil hydrochloride, which bears US NIH Compound Identifier 147352.

European Medicines Agency schedules Vardenafil hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20775. Most nations, for tariff and trade purposes, schedule vardenafil hydrochloride under HS 29350090 and SITC 51580. SMILES: CCCC1NC(C2N1[NH]C(NC2=O)C3CC(CCC3OCC)S(=O)(=O)N4CCN(CC4)CC)C.O.O.O.CL.

UNSPSC 51413211 Vardenafil hydrochloride, a Commodity code, encompasses pharmaceutical APIs and finished medications that state and local governments procure for emergency medical services, pharmacy benefit programs, and institutional health operations. Recent state and local solicitations show that this code captures purchases of branded and generic prescription medications for EMS protocols, hospital formularies, and state Medicaid or employee health benefit programs. Issuing bodies include municipal fire departments (through city purchasing offices), state health and human services agencies, and multistate cooperative purchasing alliances that aggregate demand across state and local jurisdictions. The Tampa Fire Rescue solicitation illustrates the emergency-care use case; the Texas HHS Commission RFI and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP reflect institutional and benefits-program demand. Vendors must comply with cGMP certification, FDA requirements, DSCSA chain-of-custody standards, comprehensive insurance (general liability typically $5 million per occurrence), and provide Safety Data Sheets and accessibility documentation; contracts typically run one to two years with renewal or extension options.

Recent activity centers in Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department issued IFB 26P00188 for Advanced Life Support Medications (due April 8, 2026; estimated value $40,000) supplying Labetalol, Epinephrine, Adenosine, and Diltiazem for Tampa Fire Rescue with a Small Local Business Enterprise set-aside discount of 5 percent. The Texas Health and Human Services Commission issued RFI HHS0017013 (due April 3, 2026) to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling upstream strategic procurement planning without formal award values. MMCAP, administered by the Minnesota Department of Administration, posted RFP S1070000015802 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local facilities in Minnesota and Oregon, with awards effective July 1, 2026 and contract terms of two years; pricing evaluation weighs price competitiveness at 75 percent, with vendors paying a 3 percent administrative fee on all purchases.